← Leaderboards
John C Byrd
University Of Cincinnati
$38,019,882
Attributed
$50,771,273
Total exposure
28
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$68,247,504 · 30
By mechanism
R01$14,894,947 · 8
P50$12,968,573 · 3
K12$9,663,405 · 1
P30$7,885,387 · 4
R35$6,563,421 · 1
P01$6,548,691 · 4
Top collaborators
- Jennifer A. Woyach11 shared
- Rosa Lapalombella10 shared
- Amy Jo Johnson8 shared
- Robert Alan Baiocchi5 shared
- Natarajan Muthusamy5 shared
- Susheela Tridandapani5 shared
- William E. Carson4 shared
- Kristie A Blum2 shared
Most similar at University Of Cincinnati
Same institution · by research overlap
- Erin K Hertlein$170,868
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsChronic Lymphocytic LeukemiaProgramsTumorBaseMalignant NeoplasmsResearch PersonnelLeukemiaMediatingPre-ClinicalCellsImmunotherapyApoptosisResponseLaboratoriesNeoplastic CellTargeted TreatmentInvestigationAdult LeukemiaRituximabDisease RemissionLeadGeneticSuccess
Grant awards (127)
Cancer Center Support Grant$6,245,560
P30 · FY2025 · CA · contact PI
Pharmacodynamically directed targeted therapy for leukemia$683,472
R01 · FY2025 · CA · contact PI
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$632,637
UG1 · FY2025 · CA · contact PI
NCI ETCTN Pittsburgh Cancer Consortium (PCC)$468,866
UM1 · FY2025 · CA
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$632,637
UG1 · FY2024 · CA · contact PI
NCI ETCTN Pittsburgh Cancer Consortium (PCC)$442,721
UM1 · FY2024 · CA
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$663,301
UG1 · FY2023 · CA · contact PI
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$634,586
UG1 · FY2022 · CA · contact PI
Targeted Therapy for Leukemia$971,232
R35 · FY2021 · CA · contact PI
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$481,070
UG1 · FY2021 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2021 · CA
Project 03: Leukemia Research (LR)$52,152
P30 · FY2021 · CA · contact PI
Targeted Therapy for Leukemia$914,298
R35 · FY2020 · CA · contact PI
ITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" Therapies$719,943
UG1 · FY2020 · CA · contact PI
Targeted Therapies for Richters Transformation$463,172
R01 · FY2020 · CA
Leukemia Research Program (LR)$48,693
P30 · FY2020 · CA · contact PI
Targeted Therapy for Leukemia$886,697
R35 · FY2019 · CA · contact PI
OSU K12 Training Grant in Oncology$809,498
K12 · FY2019 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$496,655
R01 · FY2019 · CA
Targeted Therapies for Richters Transformation$449,278
R01 · FY2019 · CA
Leukemia Research Program (LR)$53,293
P30 · FY2019 · CA · contact PI
Targeted Therapy for Leukemia$908,348
R35 · FY2018 · CA · contact PI
OSU K12 Training Grant for Clinical Faculty Investigators$793,532
K12 · FY2018 · CA · contact PI
Oncology Training Grant$544,263
T32 · FY2018 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$512,016
R01 · FY2018 · CA
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$501,285
R01 · FY2018 · CA · contact PI
Targeted Therapies for Richters Transformation$461,935
R01 · FY2018 · CA
Leukemia Research Program (LR)$65,564
P30 · FY2018 · CA · contact PI
Leukemia Research Program (LR)$4,572
P30 · FY2018 · CA · contact PI
Leukemia Research Program (LR)$2,399
P30 · FY2018 · CA · contact PI
Leukemia Research Program (LR)$2,390
P30 · FY2018 · CA · contact PI
Leukemia Research Program (LR)$2,022
P30 · FY2018 · CA · contact PI
Targeted Therapy for Leukemia$910,045
R35 · FY2017 · CA · contact PI
OSU K12 Training Grant for Clinical Faculty Investigators$797,702
K12 · FY2017 · CA · contact PI
Targeted Therapy for Lymphoid Malignancies$536,708
R01 · FY2017 · CA · contact PI
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$523,187
R01 · FY2017 · CA · contact PI
Oncology Training Grant$514,824
T32 · FY2017 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$512,016
R01 · FY2017 · CA
Targeted Therapies for Richters Transformation$452,551
R01 · FY2017 · CA
Novel monocyte effector function in CLL immune therapy$319,550
R01 · FY2017 · CA
Targeted Therapy for Leukemia$64,960
R35 · FY2017 · CA · contact PI
Leukemia Research Program (LR)$46,262
P30 · FY2017 · CA · contact PI
Targeted Therapy for Leukemia$914,298
R35 · FY2016 · CA · contact PI
OSU K12 Training Grant for Clinical Faculty Investigators$802,008
K12 · FY2016 · CA · contact PI
Targeted Therapy for Lymphoid Malignancies$536,708
R01 · FY2016 · CA · contact PI
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$536,570
R01 · FY2016 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$445,083
R01 · FY2016 · CA
Innate Immune Therapy for B-Cell Malignancies$381,967
P01 · FY2016 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$319,550
R01 · FY2016 · CA
Novel Immunotherapies for Lymphoid Malignancies$316,438
R01 · FY2016 · CA · contact PI
Targeted Therapy for Leukemia$65,935
R35 · FY2016 · CA · contact PI
Leukemia Research Program (LR)$36,301
P30 · FY2016 · CA · contact PI
Targeted Therapy for Leukemia$16,280
R35 · FY2016 · CA · contact PI
Targeted Therapy for Leukemia$911,328
R35 · FY2015 · CA · contact PI
OSU K12 Training Grant for Clinical Faculty Investigators$806,060
K12 · FY2015 · CA · contact PI
Targeted Therapy for Lymphoid Malignancies$536,708
R01 · FY2015 · CA · contact PI
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$527,877
R01 · FY2015 · CA · contact PI
Innate Immune Therapy for B-Cell Malignancies$381,967
P01 · FY2015 · CA · contact PI
Dual targeting of XPO1 and BTK in B cell malignancies$319,550
R01 · FY2015 · CA
Novel monocyte effector function in CLL immune therapy$319,550
R01 · FY2015 · CA
Novel Immunotherapies for Lymphoid Malignancies$316,438
R01 · FY2015 · CA · contact PI
OSU as Network Lead Academic Participating Site for the NCI NCTN$1,455,849
U10 · FY2014 · CA
OSU K12 Training Grant for Clinical Faculty Investigators$808,277
K12 · FY2014 · CA · contact PI
Targeted Therapy for Lymphoid Malignancies$520,184
R01 · FY2014 · CA · contact PI
Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies$500,541
R01 · FY2014 · CA · contact PI
Innate Immune Therapy for B-Cell Malignancies$370,509
P01 · FY2014 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$309,712
R01 · FY2014 · CA
Novel Immunotherapies for Lymphoid Malignancies$306,945
R01 · FY2014 · CA · contact PI
Experimental Therapeutics of Leukemia$2,150,499
P50 · FY2013 · CA · contact PI
Targeted Therapy for Lymphoid Malignancies$534,094
R01 · FY2013 · CA · contact PI
Innate Immune Therapy for B-Cell Malignancies$359,411
P01 · FY2013 · CA · contact PI
Novel monocyte effector function in CLL immune therapy$317,993
R01 · FY2013 · CA
Novel Immunotherapies for Lymphoid Malignancies$297,452
R01 · FY2013 · CA · contact PI
Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia$230,527
P50 · FY2013 · CA · contact PI
Administration and Operations$103,227
P50 · FY2013 · CA · contact PI
Experimental Therapeutics of Leukemia$2,295,172
P50 · FY2012 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$890,685
K12 · FY2012 · CA · contact PI
Innate Immune Therapy for B-Cell Malignancies$383,456
P01 · FY2012 · CA · contact PI
Novel Immunotherapies for Lymphoid Malignancies$316,438
R01 · FY2012 · CA · contact PI
Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia$246,231
P50 · FY2012 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$171,008
K12 · FY2012 · CA · contact PI
Administration and Operations$110,260
P50 · FY2012 · CA · contact PI
Experimental Therapeutics of Leukemia$2,185,000
P50 · FY2011 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$898,887
K12 · FY2011 · CA · contact PI
INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES$483,061
P01 · FY2011 · CA · contact PI
Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia$233,714
P50 · FY2011 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$171,008
K12 · FY2011 · CA · contact PI
Administration and Operations$104,654
P50 · FY2011 · CA · contact PI
Experimental Therapeutics of Leukemia$2,300,000
P50 · FY2010 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$898,478
K12 · FY2010 · CA · contact PI
Clinical Investigation of Epigenetic Therapy$501,619
P01 · FY2010 · CA · contact PI
INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES$500,067
P01 · FY2010 · CA · contact PI
Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia$245,839
P50 · FY2010 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$171,008
K12 · FY2010 · CA · contact PI
Administration and Operations$110,086
P50 · FY2010 · CA · contact PI
2010 Clinical Research Training Institute Summer Workshop$47,500
R13 · FY2010 · HL · contact PI
Experimental Therapeutics of Leukemia$2,300,000
P50 · FY2009 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$895,907
K12 · FY2009 · CA · contact PI
Clinical Investigation of Epigenetic Therapy$493,856
P01 · FY2009 · CA · contact PI
INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES$492,345
P01 · FY2009 · CA · contact PI
Clinical Trial Office$353,508
P30 · FY2009 · CA · contact PI
Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia$244,071
P50 · FY2009 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$171,008
K12 · FY2009 · CA · contact PI
Administration and Operations$109,293
P50 · FY2009 · CA · contact PI
Translational Training Grant in Experimental Therapeutics$578,339
K12 · FY2008 · CA · contact PI
Clinical Investigation of Epigenetic Therapy$480,497
P01 · FY2008 · CA · contact PI
INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES$478,215
P01 · FY2008 · CA · contact PI
Clinical Trial Office$334,851
P30 · FY2008 · CA · contact PI
Clinical Investigation of Epigenetic Therapy$478,381
P01 · FY2007 · CA · contact PI
INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES$447,239
P01 · FY2007 · CA · contact PI
Clinical Trial Office$297,138
P30 · FY2007 · CA · contact PI
Clinical Investigation of Epigenetic Therapy$316,101
P01 · FY2006 · CA · contact PI
Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES$305,171
R01 · FY2006 · CA · contact PI
Clinical Trial Office$172,858
P30 · FY2006 · CA · contact PI
Epigenetic Targeted Therapy for Chronic Lymphocytic Leu*$306,475
R21 · FY2005 · CA
Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES$306,290
R01 · FY2005 · CA
Molecular Markers: Response to Chemo-immunotherapy in C*$269,520
R21 · FY2005 · CA
Clinical Trial Office$167,824
P30 · FY2005 · CA
Chronic Lymphocytic Leukemia:Epigenetic Targeted Therapy$306,475
R21 · FY2004 · CA
Molecular Markers: Response to Chemo-immunotherapy in CL$294,270
R21 · FY2004 · CA
Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES$291,975
R01 · FY2004 · CA
Hu1D10 in CLL: CLINICAL AND LABORATORY STUDIES$338,683
R01 · FY2003 · CA
DEPSIPEPTIDE: A NOVEL HISTONE DEACYTLASE INHIBITOR IN L$328,188
R21 · FY2003 · CA
DEPSIPEPTIDE: A NOVEL HISTONE DEACYTLASE INHIBITOR IN L$327,910
R21 · FY2002 · CA
A PHASE 1 Study of HuD10 IN CLL/SLL PATIENTS$326,484
R21 · FY2002 · CA
CLINICAL INVESTIGATION OF THE INNATE IMMUNE SYSTEM$0
P01 · FY2002 · CA
A PHASE 1 Study of HuD10 IN CLL/SLL PATIENTS$325,561
R21 · FY2001 · CA